Literature DB >> 21135850

Cracking the moody brain: lifting the mood with ketamine.

James W Murrough1, Dennis S Charney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21135850     DOI： 10.1038/nm1210-1384

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

1.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

2.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

3.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

4.  Functional antagonists at the NMDA receptor complex exhibit antidepressant actions.

Authors:  R Trullas; P Skolnick
Journal:  Eur J Pharmacol       Date:  1990-08-21       Impact factor: 4.432

5.  Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs.

Authors:  J W Olney; J Labruyere; M T Price
Journal:  Science       Date:  1989-06-16       Impact factor: 47.728

Review 6.  Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression.

Authors:  P Skolnick; R T Layer; P Popik; G Nowak; I A Paul; R Trullas
Journal:  Pharmacopsychiatry       Date:  1996-01       Impact factor: 5.788

7.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

8.  An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors:  Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

9.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

Review 10.  Psychiatric safety of ketamine in psychopharmacology research.

Authors:  Edward B Perry; Joyce A Cramer; Hyun-Sang Cho; Ismene L Petrakis; Laurence P Karper; Angelina Genovese; Elizabeth O'Donnell; John H Krystal; D Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2007-02-16       Impact factor: 4.415
View more
  14 in total

Review 1.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

2.  Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation.

Authors:  M M Harraz; R Tyagi; P Cortés; S H Snyder
Journal:  Mol Psychiatry       Date:  2016-01-19       Impact factor: 15.992

3.  Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice.

Authors:  Qi Zhang; Fei Guo; Zhi-wen Fu; Bing Zhang; Cheng-gang Huang; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2015-12-21       Impact factor: 6.150

4. 

Authors:  D Voulliaume; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2018-06-30

5.  Antidepressant Effects of Ketamine Are Not Related to ¹⁸F-FDG Metabolism or Tyrosine Hydroxylase Immunoreactivity in the Ventral Tegmental Area of Wistar Rats.

Authors:  Pedro Porto Alegre Baptista; Lisiani Saur; Pamela Bambrilla Bagatini; Samuel Greggio; Gianina Teribele Venturin; Sabrina Pereira Vaz; Kelly Dos Reis Ferreira; Juliana Silva Junqueira; Diogo Rizzato Lara; Jaderson Costa DaCosta; Cristina Maria Moriguchi Jeckel; Régis Gemerasca Mestriner; Léder Leal Xavier
Journal:  Neurochem Res       Date:  2015-04-17       Impact factor: 3.996

6.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

7.  Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression.

Authors:  Jasper Stevens; Robert R Bies; Anantha Shekhar; Amit Anand
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

8.  Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations.

Authors:  James W Murrough
Journal:  Psychopharmacology (Berl)       Date:  2015-03-11       Impact factor: 4.530

Review 9.  Early interventions for PTSD: a review.

Authors:  Megan C Kearns; Kerry J Ressler; Doug Zatzick; Barbara Olasov Rothbaum
Journal:  Depress Anxiety       Date:  2012-08-31       Impact factor: 6.505

10.  Modulation of functional EEG networks by the NMDA antagonist nitrous oxide.

Authors:  Levin Kuhlmann; Brett L Foster; David T J Liley
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.